Mark Rogge

2.6k total citations
62 papers, 2.1k citations indexed

About

Mark Rogge is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Immunology. According to data from OpenAlex, Mark Rogge has authored 62 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pharmacology, 14 papers in Pediatrics, Perinatology and Child Health and 11 papers in Immunology. Recurrent topics in Mark Rogge's work include Antibiotics Pharmacokinetics and Efficacy (14 papers), Pharmaceutical studies and practices (8 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Mark Rogge is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (14 papers), Pharmaceutical studies and practices (8 papers) and Pharmacological Effects and Toxicity Studies (6 papers). Mark Rogge collaborates with scholars based in United States, Japan and Switzerland. Mark Rogge's co-authors include William N. Charman, Frank J. Dutko, Wei Yin, Colin W. Pouton, Susan A. Charman, Terry D. Wilson, Bruce M. Berger, Andrew Chow, R. Rex Williams and Shuchean Chien and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature reviews. Immunology.

In The Last Decade

Mark Rogge

60 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Rogge United States 24 475 458 433 350 308 62 2.1k
Lynda R. Wiseman New Zealand 33 437 0.9× 675 1.5× 101 0.2× 650 1.9× 316 1.0× 63 3.1k
Wen Chyi Shyu United States 23 501 1.1× 408 0.9× 120 0.3× 270 0.8× 228 0.7× 78 1.6k
J. Paul Monk United States 27 556 1.2× 643 1.4× 84 0.2× 838 2.4× 295 1.0× 58 3.3k
Hans Georg Eichler Austria 26 700 1.5× 200 0.4× 187 0.4× 159 0.5× 321 1.0× 52 1.9k
Yoshitaka Yano Japan 23 465 1.0× 332 0.7× 78 0.2× 424 1.2× 214 0.7× 83 1.8k
Walid M. Awni United States 30 454 1.0× 489 1.1× 145 0.3× 528 1.5× 425 1.4× 139 3.0k
Kazuaki Taguchi Japan 28 259 0.5× 1.0k 2.2× 145 0.3× 191 0.5× 224 0.7× 189 2.3k
Yalin Dong China 27 585 1.2× 582 1.3× 111 0.3× 326 0.9× 438 1.4× 150 2.3k
Noha N. Salama United States 21 151 0.3× 432 0.9× 228 0.5× 418 1.2× 127 0.4× 41 1.5k
Marco Siccardi United Kingdom 35 371 0.8× 495 1.1× 340 0.8× 400 1.1× 499 1.6× 147 3.5k

Countries citing papers authored by Mark Rogge

Since Specialization
Citations

This map shows the geographic impact of Mark Rogge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Rogge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Rogge more than expected).

Fields of papers citing papers by Mark Rogge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Rogge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Rogge. The network helps show where Mark Rogge may publish in the future.

Co-authorship network of co-authors of Mark Rogge

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Rogge. A scholar is included among the top collaborators of Mark Rogge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Rogge. Mark Rogge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Otani, Yuki, Richard Labotka, Mark Rogge, et al.. (2024). Modeling serum M‐protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone. CPT Pharmacometrics & Systems Pharmacology. 13(12). 2124–2136.
2.
Grundmann, Oliver, Parag Kumar, & Mark Rogge. (2021). Regulation of Dietary Supplements and Nutraceutical Products in the United States: An Argument for Greater Oversight and Uniform Standards. The Journal of Clinical Pharmacology. 62(1). 14–16. 7 indexed citations
3.
Rogge, Mark, Parag Kumar, & Oliver Grundmann. (2021). Front‐Line Health Care Professionals Lack Critical Knowledge in Dietary Supplement and Nutraceutical Products: A Call to Action for Comprehensive Educational Opportunities. The Journal of Clinical Pharmacology. 62(1). 17–19. 5 indexed citations
4.
5.
Yin, Wei & Mark Rogge. (2019). Targeting RNA : A Transformative Therapeutic Strategy. Clinical and Translational Science. 12(2). 98–112. 111 indexed citations
6.
He, Ping, Thomas Marbury, Wildon Farwell, et al.. (2014). Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function. The Journal of Clinical Pharmacology. 54(12). 1383–1390. 5 indexed citations
7.
Hu, Xiao, Larisa Miller, Sandra Richman, et al.. (2011). A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology. The Journal of Clinical Pharmacology. 52(6). 798–808. 91 indexed citations
8.
Li, Zhaoyang, Christopher TenHoor, Thomas Marbury, et al.. (2010). Clinical Pharmacokinetics of Tonapofylline: Evaluation of Dose Proportionality, Oral Bioavailability, and Gender and Food Effects in Healthy Human Subjects. The Journal of Clinical Pharmacology. 51(7). 1004–1014. 6 indexed citations
9.
Munafo, Alain, et al.. (2007). Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. European Journal of Clinical Pharmacology. 63(7). 647–656. 51 indexed citations
10.
Ponce, Rafael, et al.. (2006). Influenza Virus Host Response of C57Bl/6 Mice Treated with TACI-Ig. Immunopharmacology and Immunotoxicology. 28(1). 13–32. 12 indexed citations
11.
Visich, Jennifer, Kelly Byrnes-Blake, Kenneth B. Lewis, Brent Meengs, & Mark Rogge. (2006). Bioavailability and relative tissue distribution of [125I]‐recombinant human thrombin following intravenous or subcutaneous administration to non‐human primates. Journal of Thrombosis and Haemostasis. 4(9). 1962–1968. 4 indexed citations
12.
Ponce, Rafael, Linda A. Zuckerman, Jennifer Visich, et al.. (2006). Preclinical safety of recombinant human thrombin. Regulatory Toxicology and Pharmacology. 47(1). 48–58. 23 indexed citations
13.
Krejsa, Cecile M., Mark Rogge, & Wolfgang Sadée. (2006). Protein therapeutics: new applications for pharmacogenetics. Nature Reviews Drug Discovery. 5(6). 507–521. 66 indexed citations
14.
Martin, Pauline L., et al.. (2002). Safety and Systemic Absorption of Pulmonary Delivered Human IFN- β 1a in the Nonhuman Primate: Comparison with Subcutaneous Dosing. Journal of Interferon & Cytokine Research. 22(6). 709–717. 11 indexed citations
15.
Chien, Shuchean, et al.. (2002). Absence of a pharmacokinetic interaction between digoxin and levofloxacin. Journal of Clinical Pharmacy and Therapeutics. 27(1). 7–12. 6 indexed citations
16.
Rogge, Mark, et al.. (1998). Impaired Bioavailability of Interferon Beta-1a when Administered Intramuscularly by Needle-Free Injection. Drug Delivery. 5(4). 275–280. 3 indexed citations
17.
Charman, William N., et al.. (1993). Absorption of Danazol After Administration to Different Sites of the Gastrointestinal Tract and the Relationship to Single‐ and Double‐Peak Phenomena in the Plasma Profiles. The Journal of Clinical Pharmacology. 33(12). 1207–1213. 45 indexed citations
18.
Rogge, Mark, William R. Solomon, Allen J. Sedman, et al.. (1989). The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. Clinical Pharmacology & Therapeutics. 46(4). 420–428. 15 indexed citations
19.
Rogge, Mark, et al.. (1988). The theophylline-enoxacin interaction: I. Effect of enoxacin dose size on theophylline disposition. Clinical Pharmacology & Therapeutics. 44(5). 579–587. 40 indexed citations
20.
Wagner, John G., Mark Rogge, Ronald B. Natale, Kenneth S. Albert, & Gregory J. Szpunar. (1987). Single dose and steady‐state pharmacokinetics of adinazolam after oral administration to man. Biopharmaceutics & Drug Disposition. 8(5). 405–425. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lynda R. Wiseman Breakdown of academic impact, for papers by Wen Chyi Shyu Breakdown of academic impact, for papers by J. Paul Monk Breakdown of academic impact, for papers by Hans Georg Eichler Breakdown of academic impact, for papers by Yoshitaka Yano Breakdown of academic impact, for papers by Walid M. Awni Breakdown of academic impact, for papers by Kazuaki Taguchi Breakdown of academic impact, for papers by Yalin Dong Breakdown of academic impact, for papers by Noha N. Salama Breakdown of academic impact, for papers by Marco Siccardi
Rankless by CCL
2026